Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 09/29 10:00:31 pm
117.27 USD   -1.78%
10:22a JOHNSON & JOHNS : Wall Street ends lower; Nasdaq Composite drops 1%
09/29 DOW MOVERS : Mrk, cat
09/28 GLOBAL DRUG ELU : BOSTON SCIENTIFIC, JOHNSON and JOHNSON, ABBOTT LAB..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CEST
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
10:22a JOHNSON & JOHNSON : Wall Street ends lower; Nasdaq Composite drops 1%
09/29 JOHNSON & JOHNSON : Announces Agreement to Acquire Abbott Medical Optics
09/29 JOHNSON & JOHNSON : Advances Commitment to Improve Global Health and Well-Being
09/29 JOHNSON & JOHNSON : New Erythema Data Have Been Reported by Investigators at Joh..
09/29 JOHNSON & JOHNSON : Recent Findings from Johnson & Johnson Has Provided New Info..
09/29 DOW MOVERS : Mrk, cat
09/28 GLOBAL DRUG ELUTING STENTS (DES) MAR : BOSTON SCIENTIFIC, JOHNSON and JOHNSON, A..
09/28 3D SIGNATURES : TSXV-listed 3D Signatures Names Jason Flowerday as New CEO
09/27 JOHNSON & JOHNSON : Two US companies eye Seagate land in Batu Kawan
09/26 JOHNSON & JOHNSON : FDA Approves STELARA® (Ustekinumab) for Treatment of Adults ..
More news
Sector news : Pharmaceuticals - NEC
07:26aDJNovo Nordisk Announces Job Cuts
09/29DJGLAXOSMITHKLINE : Appoints New Consumer Healthcare Chief
09/29DJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:08a Medtronic's Artificial Pancreas Leads The Field
09/29 Buying Dividend Growth Stocks Without Looking; 17 Months Later.
09/29 PHILIP MORRIS INTERNATIONAL : Great Dividend Income Company With Inelastic Produ..
09/28 Obalon Therapeutics IPO May Inflate Company Prospects
09/28 VALUATION IS A MEASUREMENT OF SOUNDN : Part 1
Advertisement
Financials ($)
Sales 2016 72 075 M
EBIT 2016 21 925 M
Net income 2016 16 508 M
Finance 2016 14 428 M
Yield 2016 2,67%
P/E ratio 2016 19,97
P/E ratio 2017 17,60
EV / Sales 2016 4,25x
EV / Sales 2017 3,98x
Capitalization 320 836 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 8,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.16%320 836
ROCHE HOLDING LTD.-11.51%216 029
NOVARTIS AG-10.14%209 049
PFIZER INC.3.22%202 108
MERCK & CO., INC.17.21%171 194
GLAXOSMITHKLINE PLC19.99%104 124
More Results